Simpson Thacher represented the underwriters, led by BofA Securities, Citigroup, Goldman Sachs and J.P. Morgan, in connection with a registered offering of $31 billion in Notes by Pfizer, Inc.’s wholly-owned subsidiary, Pfizer Investment Enterprises Pte. Ltd. The Notes are fully and unconditionally guaranteed on a senior unsecured basis by Pfizer.
The Notes were issued in eight series with maturities ranging from 2025 to 2063, with proceeds intended to be used for the financing for Pfizer’s proposed acquisition of Seagen Inc. News reports noted that the offering is the fourth-largest U.S. bond sale ever and largest debt financing for a merger or acquisition this year.
Pfizer applies science and its global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development and manufacture of healthcare products, including innovative medicines and vaccines.
The Simpson Thacher team included Joseph Kaufman, Jonathan Ozner, Kirsten Harmon, Kaitlyn Posa and Elizabeth Greene (Capital Markets); Russell Light and Michael Mann (Tax); Melanie Jolson (IP); Jamin Koslowe and Guanxiong Xu (Executive Compensation and Benefits); Toby Chun and Noreen Lavan (Environmental); and Jennie Getsin (Blue Sky).